Hematology · 3 h ago
Age and Complex Karyotype Predict Mortality in Therapy-Related Myeloid Neoplasms
A retrospective cohort study of 86 adults with therapy-related myeloid neoplasms found poor overall survival, with older age and complex karyotype associated with disease-related mortality. Allogeneic transplantation was associated with longer median survival and appeared to attenuate the risk linked to complex karyotype, although the analysis was small and nonrandomized.
- Median overall survival was 11.94 months.
- Complex karyotype was present in 47% of patients.
- Age 65 or older predicted disease-related mortality.
- Transplantation appeared to attenuate complex-karyotype risk.
Researchers retrospectively analyzed 86 adults diagnosed with therapy-related myeloid neoplasms between 2007 and 2025: 31 had acute myeloid leukemia, 38 myelodysplastic neoplasms and 17 MDS/AML. Median age was 65.5 years. Of 66 patients considered candidates for active treatment, 39 were candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT), and 24 received a transplant. The study assessed overall survival and disease-related mortality.
In practice
For adults with therapy-related myeloid neoplasms, this retrospective cohort suggests that allo-HSCT may attenuate the adverse risk associated with complex karyotype: median overall survival was 29.47 months among transplant recipients versus 9.01 months among those not transplanted. However, age 65 or older remained associated with disease-related mortality regardless of transplantation. These findings may inform discussions of transplant candidacy, but the cohort was small and treatment allocation was not randomized; the results do not establish a causal transplant benefit or support changing practice on their own.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
European Journal of Haematology: Older Age and Complex Karyotype Are the Main Predictors of Mortality Irrespective of Transplantation in Therapy‐Related Myeloid Neoplasms ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.